LungCancerRx is a new podcast that features conversations among oncologists and patients. From tackling logistical obstacles to handling existential questions, these discussions aim to provide empowerment, knowledge, and hope across the lung cancer community. Eric K. Singhi, MD, a thoracic oncologist in Houston; Aakash Desai, MD, MPH, an assistant professor at the University of Alabama Birmingham’s O’Neal Cancer Center; and Fawzi Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit, cohost each episode. “We wanted to bridge the gap between provider communication and patient communication,” explains Dr. Singhi.
Why Lung Cancer Care Needs “Weed Killers” and “Crop Dusters”
Aditya Juloori, MD, discusses the importance of demystifying the role of radiation oncology in lung cancer care with Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD
26 Jun 2026
More Accuracy, Less Speed? ASCO 2026 Data Further Support Targeted Therapy in Early-Stage NSCLC
Data presented at ASCO 2026 further underscore the importance of identifying which patients with early-stage NSCLC are eligible for targeted therapies. Jamie E. Chaft, MD, discusses results from the LIBRETTO, CROWN, and EA5142 trials with LungCancerRx hosts Aakash Desai, MD, MPH, Eric K. Singhi, MD, and Fawzi F. Abu Rous, MD.
12 Jun 2026
What Do ASCO 2026 Data on NSCLC Co-mutations Mean for Practice?
Ferdinandos Skoulidis, MD, PhD, discusses data on KRAS- mutated NSCLC from ASCO 2026 with Aakash Desai, MD, MPH, Fawzi F. Abu Rous, MD, and Eric K. Singhi, MD.
1 May 2026
Neoadjuvant Therapy for Early-Stage Lung Cancer: Where Do Things Stand, and What’s Next?
Given recent advances, where do things stand for neoadjuvant therapy in patients with NSCLC? The panel discusses current considerations and what important questions may soon be answered.
Patrick Forde MBBCh, PhD, a thoracic medical oncologist at Johns Hopkins University in Baltimore, Maryland, and professor of immuno-oncology at Trinity College Dublin discusses current multidisciplinary approaches to perioperative care in NSCLC with Eric K. Singhi, MD, a thoracic oncologist in Houston, and Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O’Neal Cancer Center.
13 Mar 2026
Lung Cancer Myths: Separating Fact From Fiction
From screening to treatment, myths and misperceptions about lung cancer present challenges for physicians and patients. From setting the record straight on surgical approaches to setting higher expectations for treatment outcomes, the LungCancerRx panel tackles key questions currently faced in practice.
27 Feb 2026
“Just Doesn’t Make Sense”: What’s Missing When It Comes to Diagnosing Lung Cancer
Despite notable recent advances in lung cancer treatment, early diagnosis remains a challenge. From problems with screening criteria to changes in disease demographics, the LungCancerRx panel explains why the only solution is “education, education, education.”
5 Dec 2025
“We Want to Stop the Gatekeeping of Information”: The Origin of LungCancerRx
To cap off the first year of the LungCancerRx podcast, cohosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, share how they first came together and what they see as their mission for the series moving forward. “I think we want to stop the gatekeeping of information,” Dr. Singhi explained.
21 Nov 2025
“Absolute Flood” of ADCs and Key Data Lead to “Good Challenges” in EGFR-Mutated NSCLC
In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome Julia Rotow, MD to the conversation.
“I think we’ve been very lucky, in the world of EGFR-mutated lung cancer, that it has gotten so complicated,” explains Julia Rotow, MD, clinical director of the Lowe Center for Thoracic Oncology and director of clinical research at the Dana-Farber Cancer Institute in Boston. Dr. Rotow explains how key data from the HARMONi, COMPEL, and MARIPOSA-2 studies and a wave of new treatment options on the horizon have led to “good challenges” in non-small cell lung cancer care.
26 Sept 2025
“It Unlocks This Whole World”: Better Understanding of Lung Cancer Is Generating Better Outcomes
In this episode of LungCancerRx, the experts talk about key trials presented at the World Conference on Lung Cancer, and the rapidly shifting landscape in lung cancer treatment, which now can be treated as multiple different diseases. Cohost Eric Singhi, MD, is joined by Bruna Pellini, MD, Antonio Calles, MD, and Stephen Liu, MD.
12 Sept 2025
“Milestone” in EGFR-Positive NSCLC: The Importance of Options for Patient-Centered Care
In this episode of LungCancerRx, the experts talk about the FLAURA2 and HARMONi data presented at the World Conference on Lung Cancer and what the findings mean for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Recorded onsite in Barcelona, Spain, cohost Eric Singhi, MD, from Houston, Texas, is joined by Bruna Pellini, MD, from Moffitt Cancer Center and Research Institute in Tampa, Florida; Antonio Calles, MD, from Hospital General Universitario Gregorio Marañón in Madrid, Spain; and Stephen Liu, MD, from Lombardi Comprehensive Cancer Center of Georgetown University in Washington, DC.
22 Aug 2025
“What I Tell My Patients”: Making Sense of New Treatment Options in EGFR-positive NSCLC
In this episode of LungCancerRx, Eric Singhi, MD, Aakash Desai, MD, MPH, and Fawzi F. Abu Rous, MD, welcome back Christine M. Lovly, MD, PhD, to talk about the complexities of treating advanced EGFR-positive NSCLC. Dr. Lovely shares how she talks with patients about the latest data and recent trials.
8 Aug 2025
Say No to Jargon, Yes to Testing: Oncologists Face Tough Patient Conversations in NSCLC
As oncologists stand on “the cutting edge” of neoadjuvant treatment for EGFR-mutated lung cancer, how should they conduct complex conversations with patients? Christine M. Lovly, MD, PhD, joins hosts Aakash Desai, MD, MPH; Eric K. Singhi, MD; and Fawzi F. Abu Rous, MD, for an honest discussion about current challenges.
11 Jul 2025
Empowered Choices: “The Most Important Conversations” Oncologists Can Have With NSCLC Patients
When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” says patient advocate Jill Feldman. In the second episode of the LungCancerRx video podcast, cohosts Fawzi F. Abu Rous, MD, a thoracic medical oncologist at Henry Ford Health in Detroit; Eric K. Singhi, MD, a thoracic oncologist in Houston; and Aakash Desai, MD, MPH, an assistant professor at the University of Alabama at Birmingham’s O’Neal Cancer Center, ask Feldman about how physicians can better empower patients when making difficult therapy choices. “I started using ‘informed decision-making’ because you cannot have ‘shared decision-making’ if patients aren’t completely informed,” she explains.
12 Jun 2025
Empowered Voices: The Journey to Patient Advocacy
Patient advocate Jill Feldman shares her lung cancer journey with hosts Eric K. Singhi, Aakash Desai, and Fawzi Abu Rous, emphasizing patient-centered care and effective communication in this interview.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
3 ratings
Spotify
5.0 / 5
2 ratings
Podcast Authority Score: 12 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
12
Social presence
0
YouTube
0
Engagement
32
Contact Lung Cancer Rx
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Lung Cancer Rx?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
